Kane Biotech Inc.
TSXV: KNE.V0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Toronto Stock Exchange Ventures
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Robert Huizinga
- Employees
- 32
- Headquarters
- Winnipeg, Canada
- IPO year
- 2003
- Market cap
- CA$6.4M
- Website
- https://kanebiotech.com
Loading KNE…
Loading profile data…Frequently asked questions about KNE
What does Kane Biotech Inc. (KNE.V) do?
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops pet oral care products under the StrixNB and bluestem brands; animal and human wound care solutions under the Dispersin...
Where does KNE.V trade?
Kane Biotech Inc. (KNE.V) trades on the Toronto Stock Exchange Ventures.
What sector is KNE.V in?
Kane Biotech Inc. (KNE.V) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Kane Biotech Inc.?
Robert Huizinga is the chief executive officer of Kane Biotech Inc. (KNE.V).
Where is Kane Biotech Inc. headquartered?
Kane Biotech Inc. is headquartered in Canada.
Does KNE.V pay a dividend?
Kane Biotech Inc. (KNE.V) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did KNE.V go public?
Kane Biotech Inc. (KNE.V) completed its initial public offering in 2003.